AGL 38.05 Increased By ▲ 0.48 (1.28%)
AIRLINK 131.20 Decreased By ▼ -1.30 (-0.98%)
BOP 5.59 Decreased By ▼ -0.05 (-0.89%)
CNERGY 3.79 Increased By ▲ 0.02 (0.53%)
DCL 8.75 Decreased By ▼ -0.12 (-1.35%)
DFML 40.82 Decreased By ▼ -0.18 (-0.44%)
DGKC 88.02 Decreased By ▼ -2.14 (-2.37%)
FCCL 35.12 Increased By ▲ 0.04 (0.11%)
FFBL 66.00 Decreased By ▼ -0.50 (-0.75%)
FFL 10.34 Increased By ▲ 0.19 (1.87%)
HUBC 108.71 Increased By ▲ 2.31 (2.17%)
HUMNL 14.10 Increased By ▲ 0.70 (5.22%)
KEL 4.81 Decreased By ▼ -0.05 (-1.03%)
KOSM 6.85 No Change ▼ 0.00 (0%)
MLCF 41.42 Decreased By ▼ -0.38 (-0.91%)
NBP 59.53 Increased By ▲ 0.95 (1.62%)
OGDC 180.61 Decreased By ▼ -0.64 (-0.35%)
PAEL 25.43 Decreased By ▼ -0.27 (-1.05%)
PIBTL 5.89 Increased By ▲ 0.06 (1.03%)
PPL 145.25 Decreased By ▼ -3.15 (-2.12%)
PRL 23.28 Increased By ▲ 0.06 (0.26%)
PTC 15.25 Increased By ▲ 0.01 (0.07%)
SEARL 67.89 Decreased By ▼ -0.90 (-1.31%)
TELE 7.23 Decreased By ▼ -0.01 (-0.14%)
TOMCL 35.75 Decreased By ▼ -0.25 (-0.69%)
TPLP 7.45 Increased By ▲ 0.05 (0.68%)
TREET 14.10 Decreased By ▼ -0.14 (-0.98%)
TRG 50.51 Decreased By ▼ -0.34 (-0.67%)
UNITY 26.40 No Change ▼ 0.00 (0%)
WTL 1.22 Increased By ▲ 0.01 (0.83%)
BR100 9,764 Decreased By -4.1 (-0.04%)
BR30 29,497 Increased By 97.1 (0.33%)
KSE100 91,850 Decreased By -87.8 (-0.1%)
KSE30 28,657 Decreased By -87.1 (-0.3%)
World

China exploring ways to mix different COVID vaccines to improve efficacy

  • Gao says one option is to adjust the dosage, the interval between doses, or increase the number of doses while the second route is to mix vaccines that use different technologies
  • More attention should be given to developing mRNA vaccines as the technology provided an opportunity for breakthroughs in treating all kinds of illnesses: health expert
Published April 11, 2021

(Karachi) In a major development, China is now exploring ways to mix different Covid-19 vaccines to address the relatively low efficacy of its existing jabs, local media reported on Sunday.

Top Chinese health expert Dr Gao Fu, who heads the Centre for Disease Control and Prevention, said that the authorities should solve the low efficacy issue of existing vaccines and try to improve them.

He said that one option is to adjust the dosage, the interval between doses, or increase the number of doses. "The second route is to mix vaccines that use different technologies," he maintained.

He stated that researchers should not ignore mRNA vaccines just because there are already several coronavirus jabs in the country. "More attention should be given to developing mRNA vaccines as the technology provided an opportunity for breakthroughs in treating all kinds of illnesses such as infectious diseases, HIV/AIDS, cancer and genetic diseases," Gao pointed out.

Currently, none of China's jabs conditionally approved for the market are mRNA vaccines, but products that use the technology include those by US pharma giant Pfizer and German start-up BioNTech, as well as by Moderna.

Three Chinese inactivated vaccines are currently available, including one made by Sinovac. Its vaccines had an efficacy rate of 50.4 percent in trials in Brazil, and 83.5 percent from separate trials in Turkey.

Sinopharm says its two inactivated vaccines have efficacy rates of 79 percent and 72.5 respectively, while CanSino says its product has an efficacy rate of 75 percent.

Comments

Comments are closed.